Companion Animal Specialty Drugs Market By Type (Vaccines, Antibiotics, Parasiticides, and Other), By Application (Dogs, Cats, and Others), Industry Trends, Estimation & Forecast, 2023-2030

Market Overview

Veterinary drug refers to drug intended for use in the diagnosis, cure, treatment, mitigation, or prevention of disease in animals.Veterinary medicines are used to prevent diseases in animals, including animals used for food production. The veterinary drugs are given to animals through feed, drinking water, or by injection.The veterinary drugs may result in residues of these drugs in animal products like milk, meat, and egg.

Market Dynamics

Increasing number of Companion animals with diseases, According to the study, Feline leukemia virus (FeLV) is one of the common infectious diseases in cats, affecting between 2 and 3% of all cats in the United States. In the United States each year 6,000 to 7,000 documented cases of rabies in animals. According to FDA, there are more than 500 cases of dilated cardiomyopathy (DCM) in dogs eating certain types of food.The U.S. Food and Drug Administration (FDA) has identified 16 brands of dog food which had reported cases of DCM. The top three brands, according to the FDA, are Acana, Zignature, and Taste of the Wild.Growing awareness regarding the spread of diseases from animals to humans are key driving factors of the market. According to World Health Organization (WHO), 13 zoonoses are responsible for 2.2 million human deaths every year. Around 95% of human cases of rabies are due to dog bites. Rabies kills nearly 60,000 people worldwide, mostly children each year.Cat bites have higher rate of infection than dog bites. In the United States, approximately 4.5 million persons are bitten by dogs each year, of which 316,000 are treated in the emergency department, and 9,500 are hospitalized.However, Lack of medications for certain animal disease might hamper market growth. Increasing regulatory approvals and clinical studies on animal specialty drugs would provide lucrative opportunities for the market in coming years.

Market Segmentation

Global Companion Animal Specialty Drugs market is mainly classified based on Type, Application. Type is further segmented into Vaccines, Antibiotics, Parasiticides, Other. Vaccines sowed significant growth due to the increasing investment by the companies to develop new vaccination and commercialization of new products. For instance, Boehringer Ingelheim has invested $76 million on its site in Athens, Georgia. The investment doubled the company’s capacity to produce vaccines for pets in the United States and around the world. The animal health sector invests nearly $3 billion in developing new medicines for animals. These tools help veterinarians, pet owners and farmers protect and treat their animals when disease strikes. By Application, the market is further divided into Dogs, Cats, Other.

Regional Analysis

Based on geography, the global Companion Animal Specialty Drugs market is divided into North America, Europe, Asia-Pacific, South America, and Middle East & Africa. North America is further divided in the U.S., Canada, and Mexico, whereas Europe consists of the UK, Germany, France, Italy, and Rest of Europe. Asia-Pacific is segmented into India, China, Japan, South Korea, and Rest of Asia-Pacific. The South America region includes Brazil, Argentina, and the Rest of South America, while the Middle East & Africa is categorized into GCC Countries, Egypt, South Africa, and Rest of Middle East & Africa.

North America is dominating the global Companion Animal Specialty Drugs market, due to increasing regulatory approvals for companion animal drugs. For instance, the U.S. Food and Drug Administration (FDA) has approved BRAVECTO PLUS topical solution for cats. BRAVECTO PLUS is an extended-duration, broad-spectrum combination topical solution for cats, indicated for both external and internal parasite infestations. Moreover, the U.S. Department of Agriculture has approved a license for Nobivac Canine Flu Bivalent vaccine. It is the first vaccine to control disease associated with both canine influenza virus (CIV) H3N2 and canine influenza virus H3N8.

Europe has shown significant growth due to increasing investment for animal health, commercialization of new products, and competitive strategy to develop and expand the business globally. Europe Companion Animal Specialty Drugs market is estimated to reach $4,974.6 Million.

Competitive landscape

Key players operating in the Companion Animal Specialty Drugs industry include Boehringer Ingelheim, Zoetis, Elanco Animal Health, Bayer Animal Health, MSD Tiergesundheit, Virbac Tierarzneimittel, Dechra Veterinary Products, Ceva Animal Health (IDT Biologika), Vetoquinol, AniMedica GmbH, Bela-Pharm GmbH, Chevita GmbH, CP-Pharma, Dopharma International B.V., Ecuphar GmbH, HIPRA Deutschland, Selectavet, Serumwerk Bernburg, Veyx Pharma, WDT Wirtschaftsgenossenschaft.

Increasing commercialization of new products, strategic advancement between companies to expand their business, increasing investment for animal health and regulatory approval for animal medication are the key factors boosting the global Companion Animal Specialty Drugs market. For instance, on January 6, 2020, Boehringer Ingelheim’s U.S. Animal Health Business has introduced a vaccine to protect poultry from three diseases. VAXXITEK HVT+IBD+ND provides a strong immune foundation and optimized protection against Marek’s Disease, Infectious Bursal Disease, and Newcastle Disease.

Companion Animal Specialty Drugs Market Key Segments

By Type
• Vaccines
• Antibiotics
• Parasiticides
• Other

By Application
• Dogs
• Cats
• Other

By Geography

• North America
o The U.S.
o Canada
o Mexico
• Europe
o U.K
o Germany
o France
o Italy
o Rest of Europe
• Asia Pacific
o India
o China
o Japan
o South Korea
o Rest of Asia Pacific
• South America
o Brazil
o Argentina
o Rest of South America
• Middle East & Africa
o GCC Countries
o Egypt
o South Africa
o Rest of Middle East & Africa

Key Global Companion Animal Specialty Drugs Industry Players

• Boehringer Ingelheim
• Zoetis
• Elanco Animal Health
• Bayer Animal Health
• MSD Tiergesundheit
• Virbac Tierarzneimittel
• Dechra Veterinary Products
• Ceva Animal Health (IDT Biologika)
• Vetoquinol
• AniMedica GmbH
• Bela-Pharm GmbH
• Chevita GmbH
• CP-Pharma
• Dopharma International B.V.
• Ecuphar GmbH
• HIPRA Deutschland
• Selectavet
• Serumwerk Bernburg
• Veyx Pharma
• WDT Wirtschaftsgenossenschaft

Table of Content

1. Market Introduction
1.1. Executive Summary
1.2. Market Definition
1.3. Market Scope

2. Research Methodology
2.1. Primary Research
2.2. Research Methodology
2.3. Assumptions & Exclusions
2.4. Secondary data sources

3. Companion Animal Specialty Drugs Market Overview
3.1. Report Segmentation & Scope
3.2. Key Market Trend
3.3. Drivers
3.3.1. Increasing number of Companion animals with diseases
3.3.2. Growing awareness regarding the spread of diseases from animals to humans
3.4. Restraints
3.4.1. Lack of medications for certain animal disease
3.5. Opportunity
3.5.1. Increasing regulatory approvals and clinical studies on animal specialty drugs
3.6. Porter’s Five Forces Analysis
3.6.1. Porter’s Five Forces Analysis
3.7. Market Share Analysis

4. Type Overview
4.1. Introduction
4.1.1. Market Size & Forecast
4.2. Vaccines
4.2.1. Market Size & Forecast
4.3. Antibiotics
4.3.1. Market Size & Forecast
4.4. Parasiticides
4.4.1. Market Size & Forecast
4.5. Other
4.5.1. Market Size & Forecast

5. Application Overview
5.1. Introduction
5.1.1. Market Size & Forecast
5.2. Dogs
5.2.1. Market Size & Forecast
5.3. Cats
5.3.1. Market Size & Forecast
5.4. Other
5.4.1. Market Size & Forecast

6. Companion Animal Specialty Drugs Market Regional Overview
6.1. Introduction
6.1.1. Market Size & Forecast
6.2. North America Companion Animal Specialty Drugs Market
6.2.1. North America Market Size & Forecast, By Country
6.2.2. North America Market Size & Forecast, By Type
6.2.3. North America Market Size & Forecast, By Application
6.2.4. The U.S.
6.2.4.1. Market Size and Forecast
6.2.5. Canada
6.2.5.1. Market Size and Forecast
6.2.6. Mexico
6.2.6.1. Market Size and Forecast
6.3. Europe Companion Animal Specialty Drugs Market
6.3.1. Europe Market Size & Forecast, By Country
6.3.2. Europe Market Size & Forecast, By Type
6.3.3. Europe Market Size & Forecast, By Application
6.3.4. Germany
6.3.4.1. Market Size and Forecast
6.3.5. France
6.3.5.1. Market Size and Forecast
6.3.6. UK
6.3.6.1. Market Size and Forecast
6.3.7. Italy
6.3.7.1. Market Size and Forecast
6.3.8. Spain
6.3.8.1. Market Size and Forecast
6.3.9. Rest of Europe
6.3.9.1. Market Size and Forecast
6.4. Asia-Pacific Companion Animal Specialty Drugs Market
6.4.1. Asia-Pacific Market Size & Forecast, By Country
6.4.2. Asia-Pacific Market Size & Forecast, By Type
6.4.3. Asia-Pacific Market Size & Forecast, By Application
6.4.4. Japan
6.4.4.1. Market Size and Forecast
6.4.5. China
6.4.5.1. Market Size and Forecast
6.4.6. Australia
6.4.6.1. Market Size and Forecast
6.4.7. India
6.4.7.1. Market Size and Forecast
6.4.8. South Korea
6.4.8.1. Market Size and Forecast
6.4.9. Rest of Asia-Pacific
6.4.9.1. Market Size and Forecast
6.5. South America Companion Animal Specialty Drugs Market
6.5.1. South America Market Size & Forecast, By Country
6.5.2. South America Market Size & Forecast, By Type
6.5.3. South America Market Size & Forecast, By Application
6.5.4. Brazil
6.5.4.1. Market Size and Forecast
6.5.5. Argentina
6.5.5.1. Market Size and Forecast
6.5.6. Rest of South America
6.5.6.1. Market Size and Forecast
6.6. Middle East & Africa Companion Animal Specialty Drugs Market
6.6.1. Middle East & Africa Market Size & Forecast, By Country
6.6.2. Middle East & Africa Market Size & Forecast, By Type
6.6.3. Middle East & Africa Market Size & Forecast, By Application
6.6.4. GCC Countries
6.6.4.1. Market Size and Forecast
6.6.5. Egypt
6.6.5.1. Market Size and Forecast
6.6.6. South Africa
6.6.6.1. Market Size and Forecast
6.6.7. Rest of Middle East & Africa
6.6.7.1. Market Size and Forecast

7. Company Profile
7.1. Boehringer Ingelheim
7.1.1. Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.1.2. Boehringer Ingelheim Product Category, Application, and Specification
7.1.3. Boehringer Ingelheim Financial Performance (2016-2018)
7.1.4. Main Business/Business Overview
7.2. Zoetis
7.3. Elanco Animal Health
7.4. Bayer Animal Health
7.5. MSD Tiergesundheit
7.6. Virbac Tierarzneimittel
7.7. Dechra Veterinary Products
7.8. Ceva Animal Health (IDT Biologika)
7.9. Vetoquinol
7.10. AniMedica GmbH
7.11. Bela-Pharm GmbH
7.12. Chevita GmbH
7.13. CP-Pharma
7.14. Dopharma International B.V.
7.15. Ecuphar GmbH
7.16. HIPRA Deutschland
7.17. Selectavet
7.18. Serumwerk Bernburg
7.19. Veyx Pharma
7.20. WDT Wirtschaftsgenossenschaft